Cancer Research UK backs Hummingbird’s cancer treatment development

By Vassia Barba

- Last updated on GMT

(Image: Getty/Design Cells)
(Image: Getty/Design Cells)

Related tags Cancer research uk Cancer Hummingbird Bioscience funding

Cancer Research UK to support the clinical development of Hummingbird’s investigative cancer treatment which has the potential to fight drug resistant tumours.

Hummingbird Bioscience, a biotechnology company developing cancer therapeutics, announced a partnership with Cancer Research UK charity to move its cancer treatment HMBD-001 into Phase I clinical trials.

Under the agreement, Cancer Research UK’s Centre for Drug Development will fund the program, manufacture the clinical grade antibody, and conduct the trial under the charity organization’s clinical development partnerships scheme.

HMBD-001, which was developed using Hummingbird’s rational antibody discovery platform, targets the HER3 receptor, obstructing it from binding to other cancer-associated proteins.

It is being investigated as a treatment for multiple solid tumours, including breast, gastric, pancreatic, ovarian, and lung cancers. According to Cancer Research UK, the treatment could also be effective against drug resistant cancers, as it ‘completely turns off’ the HER3 signal responsible for cancer cells’ growth.

“For many people with cancer, targeted treatments can work in the short term, but drug resistance sometimes leads to the eventual return of their tumour,” ​Nigel Blackburn, Cancer Research UK’s director of drug development, said in a statement, adding that HMBD-001 has the potential to overcome the key mechanism of drug resistance.

Following the completion of Phase I trials, Hummingbird will have the option to acquire the rights to the clinical trial results and further advance the program, otherwise Cancer Research UK will have the right to take the program forward in all indications.

Related news

Show more

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 25-Apr-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Related suppliers

Follow us


View more